Ki:elements Detects Alzheimer’s Pathology via Automated Phone Call: Study Validates Speech Biomarker Across Five European Cohorts

Why It Matters

By offering a non‑invasive, automated screen that correlates with core AD biomarkers, SB‑C can dramatically lower recruitment costs and accelerate enrollment for early‑intervention trials, reshaping how biopharma identifies eligible participants.

Key Takeaways

• SB-C distinguishes MCI from unimpaired across five European cohorts
• AI voice calls assess speech in 10 minutes, no clinician needed
• AUC up to 0.82 for tau, 0.74 for amyloid detection
• Multilingual validation covers Spanish, Catalan, German, English, Swedish
• Enables cheaper, faster pre‑screening for Alzheimer’s clinical trials

Pulse Analysis

The rise of digital biomarkers has opened new pathways for early disease detection, and speech analysis sits at the forefront of this trend. Unlike traditional neuropsychological tests that require in‑person administration, ki:elements’ SB‑C leverages natural language processing to capture subtle changes in speech rhythm, pause patterns, and lexical choice. These micro‑variations reflect underlying neural efficiency, allowing a 10‑minute phone call to serve as a proxy for cognitive health. As regulators and payers increasingly recognize the validity of AI‑derived metrics, speech‑based tools are poised to become a staple in preventive neurology.

In the recent multi‑site validation, 736 participants from Spain, the UK, Germany, and Sweden completed the automated assessment in their native language. The study reported robust convergent validity with gold‑standard instruments such as the MMSE and PACC‑5, while also demonstrating discriminative power against cerebrospinal fluid biomarkers. Notably, the SB‑C achieved an area‑under‑the‑curve of 0.82 for phosphorylated tau‑181, a figure comparable to many imaging modalities, and 0.74 for amyloid‑beta positivity. The multilingual performance—spanning Spanish, Catalan, German, English, and Swedish—underscores the platform’s scalability across diverse populations.

For pharmaceutical sponsors, the practical implications are significant. Recruiting participants for Alzheimer’s prevention trials traditionally involves costly lumbar punctures or PET scans to confirm biomarker status. SB‑C offers a low‑cost, remote pre‑screen that can enrich trial pools with individuals most likely to meet biomarker‑positive criteria, thereby reducing screen‑fail rates and shortening timelines. As the industry shifts toward decentralized trial models, tools like ki:elements’ Mili platform provide a seamless, patient‑centric solution that aligns with both regulatory expectations and the demand for faster, more efficient drug development.